Download PDF
Semin Thromb Hemost 1998; 24(5): 423-430
DOI: 10.1055/s-2007-996034
Copyright © 1998 by Thieme Medical Publishers, Inc.

Resistance to Activated Protein C in Women Using Oral Contraceptives

Michael Spannagl* , Andrea Dick* , Anita Assmann† , Lothar Heinemann‡ , Wolfgang Schramm*
  • *Ludwig Maximilians University Munich, Klinikum Innenstadt, Dept. of Hemostasis and Angiology, Munich, Germany;
  • †ZEG-Centre for Epidemiology and Health Research Berlin, Zepernick, Germany; and
  • ‡ZEG-Centre for Epidemiology and Health Research Berlin, Zepernick, Germany; Dept. of Epidemiology and Biostatistics, McGill University Montreal, Canada; Potsdam Institute of Pharmacoepidemiology and Technology Assessment, Potsdam, Germany.
Further Information

Publication History

Publication Date:
06 February 2008 (online)

  PDF Download  Permissions and Reprints

Abstract

Resistance to activated protein C (APC resistance) is an important and common risk factor for deep vein thrombosis. The majority of patients with APC resistance carry a mutation on the factor V gene at nucleotid position 1691 (G/A), called factor V Leiden mutation. Besides the factor V Leiden mutation several acquired risk factors like lupus anticoagulant, elevated levels of acute phase proteins (increased plasma levels of factor VIII and fibrinogen), pregnancy, or the use of oral contraceptives are known to induce APC resistance in plasma. We studied the effect of oral contraceptives (OC) on hemostasis variables known to be risk factors for venous thromboembolism, especially looking for acquired APC resistance and the plasmatic factors of the protein C system. We studied 821 women, who were randomly selected and enrolled in the BATER- cohort study (Bavarian Thromboembolic Risk Study), which was carried out in Bavaria (Germany) from 1996 to 1997. Current use of any OC type compared with noncurrent use showed a significantly impaired response to APC. There was no difference in APC response among women currently using OCs of different generations. Coagulation factor VIII was the only factor of the protein C pathway that was not altered under OC use. All other plasmatic factors of the protein C system changed in the expected range as described before. On the other hand, coagulation factor VIII was the only factor of the protein C system which negatively correlated with the APC response in the assays applied. Thus, APC resistance is significantly lower in OC users than in nonusers but cannot be attributed to increased factor VIII levels. Whether a decreased response to APC in OC users is of clinical relevance has to be proven in further studies.

Keywords:

Acquired APC resistance - oral contraceptives - factor VIII: C - Bavarian Thyromboembolic Risk Study - factor V Leiden

      >